Article

Once-daily bromfenac 0.09% approved

The FDA has approved a supplemental new drug application for a once-daily bromfenac 0.09% ophthalmic solution (Bromday [formerly called XiDay], ISTA Pharmaceuticals) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

Irvine, CA-The FDA has approved a supplemental new drug application for a once-daily bromfenac 0.09% ophthalmic solution (Bromday [formerly called XiDay], ISTA Pharmaceuticals) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction, according to the company.

The drug should be available before the end of the year, and the company’s twice-daily formulation of bromfenac 0.09% (Xibrom), marketed since 2005, will be discontinued early next year.

“We believe the convenience of a once-daily eye drop will help with treatment compliance and benefit patients recovering from cataract surgery,” said Vicente Anido Jr., PhD, president and chief executive officer of ISTA.

“Since the . . . approval process required additional clinical investigations beyond those conducted for the original approval of [the twice-daily solution], we are seeking a 3-year exclusivity period under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act,” he added.

The new drop is approved for once-daily dosing beginning 1 day before surgery, on the day of surgery, and continuing for the first 14 days after surgery. In studies, the most commonly reported adverse reactions, in 2% to 7% of patients each, were abnormal sensation in the eye, conjunctival hyperemia, and eye irritation (including burning/stinging).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.